As the Vice President of Integrated Drug Discovery at Syngene International Limited, Alan Collis plays a pivotal role in shaping the future of drug development through his leadership of the SynVent team. With a robust background in drug discovery and development, Alan brings a wealth...
As the Vice President of Integrated Drug Discovery at Syngene International Limited, Alan Collis plays a pivotal role in shaping the future of drug development through his leadership of the SynVent team. With a robust background in drug discovery and development, Alan brings a wealth of expertise across various domains, including Early Clinical, DMPK (Drug Metabolism and Pharmacokinetics), Preclinical Safety, and Medicinal Chemistry. His multifaceted insights enable him to effectively guide projects from initial concept through to clinical trials, ensuring that novel molecules progress seamlessly into Phase I and beyond.
Over the past five years, Alan has successfully led teams through critical phases of clinical development, with notable achievements including two projects advancing into Phase II trials and five through the Investigational New Drug (IND) application process. His strategic leadership and collaborative approach have been instrumental in fostering cross-disciplinary partnerships that integrate Biology, Chemistry, CMC (Chemistry, Manufacturing, and Controls), DMPK, and Preclinical Safety. This holistic perspective not only enhances the efficiency of drug development but also accelerates the timeline for bringing innovative therapies to patients.
Alan's expertise in DMPK and ADME (Absorption, Distribution, Metabolism, and Excretion) allows him to navigate the complexities of drug formulation and safety profiling, ensuring that each candidate meets the rigorous standards required for clinical success. His proficiency in LC-MS (Liquid Chromatography-Mass Spectrometry) and translational medicine further strengthens his capability to lead change and drive impactful results in oncology and other therapeutic areas. Through his commitment to excellence and innovation, Alan Collis continues to make significant contributions to the field of drug discovery, positioning Syngene International Limited as a leader in integrated drug development solutions.
